<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        18-5444-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ATACAND PLUS TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        75.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CHEPLAPHARM Arzneimittel GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The name of your medicine is Atacand Plus.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Candesartan cilexetil belongs to a group of medicines called angiotensin II receptor antagonists. It makes your blood vessels relax and widen. This helps to lower your blood pressure.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochlorothiazide belongs to a group of medicines called diuretics (water tablets). It helps your body to get rid of water and salts like sodium in your urine. This helps to lower your blood pressure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is used for treating high blood pressure (hypertension) in adult patients. It contains two active ingredients: candesartan cilexetil and hydrochlorothiazide. These work together to lower your blood pressure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor may prescribe Atacand Plus if your blood pressure has not been properly controlled by candesartan cilexetil or hydrochlorothiazide alone.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p dir="ltr">Do not take Atacand Plus if you are pregnant, think you might be pregnant or considering becoming pregnant. You must tell your doctor if you think you are (or might become) pregnant. Atacand Plus may cause serious harm or even death to your baby if used during pregnancy (see Pregnancy section).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Do not take Atacand Plus if:</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to candesartan cilexetil or hydrochlorothiazide or any of the other ingredients of Atacand Plus (see section&nbsp;6).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to sulphonamide medicines. If you are not sure if this applies to you, please ask your doctor.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe kidney problems.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe liver disease or biliary obstruction (a problem with the drainage of bile from the gall bladder).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have persistently low levels of potassium in your blood.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have persistently high levels of calcium in your blood.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had gout.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Atacand Plus.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Take special care with Atacand Plus</strong></p><p dir="ltr">Before you take, or whilst you are taking Atacand Plus, tell your doctor if:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have heart, liver or kidney problems.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have recently had a kidney transplant.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are vomiting, have recently had severe vomiting, or have diarrhoea.</p><p dir="ltr">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a disease of the adrenal gland called Conn&rsquo;s syndrome (also&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; called primary hyperaldosteronism).</p><p dir="ltr">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a disease called systemic lupus erythaematosus (SLE)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have low blood pressure</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a stroke.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had allergy or asthma.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;if you are taking any of the following medicines used to treat high blood pressure:</p><p dir="ltr">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE‑inhibitor (for example enalapril, lisinopril, ramipril, etc), in particular if you have diabetes‑related kidney problems.</p><p dir="ltr">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p dir="ltr">- If you have had skin cancer or if you develop a suspicious skin lesion during the</p><p dir="ltr">treatment. Treatment with hydrochlorothiazide, particularly long term use with high</p><p dir="ltr">doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin</p><p dir="ltr">cancer). Limit exposure to sunlight and protect your skin when exposed to sun while</p><p dir="ltr">taking Atacand Plus.</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; If you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking Atacand Plus. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulfonamide allergy, you can be at higher risk of developing this.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; if you have ever had breathing or lung problems (including inflammation or fluid accumulation in the lungs) after taking hydrochlorothiazide. If you develop severe shortness of breath or difficulty breathing after taking Atacand plus, consult a doctor immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor may need to check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p dir="ltr">&nbsp;</p><p dir="ltr">See also information under the heading &ldquo;Do not take Atacand Plus&rdquo;.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor may want to see you more often and do some tests if you have any of these conditions.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are going to have an operation, tell your doctor or dentist that you are taking Atacand Plus. This is because Atacand Plus, when combined with some anaesthetics, may cause an excessive drop in blood pressure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Atacand Plus may cause increased sensitivity of the skin to sun.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Use in children</p><p dir="ltr">There is no experience with the use of Atacand Plus in children (below the age of 18&nbsp;years). Therefore Atacand Plus should not be given to children.</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr"><strong>Using other medicines</strong></p><p dir="ltr">Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription. Atacand Plus can affect the way some other medicines work and some medicines can have an effect on Atacand Plus. If you are using certain medicines, your doctor may need to do blood tests from time to time.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In particular, tell your doctor if you are using any of the following medicines as your doctor may need to change your dose and/or take other precautions:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to help lower your blood pressure, including beta-blockers, aliskiren- containing medicines, diazoxide and Angiotensin Converting Enzyme<strong> </strong>(ACE)<strong> </strong>inhibitors such as enalapril, captopril, lisinopril or ramipril.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines to relieve pain and inflammation).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetylsalicylic acid (if you are taking more than 3&nbsp;g each day) (medicine to relieve pain and inflammation).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium or Vitamin D supplements.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to lower your cholesterol, such as colestipol or cholestyramine.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for diabetes (tablets or insulin).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to control your heart beat (antiarrhythmic agents) such as digoxin and beta‑blockers.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that can be affected by potassium blood levels such as some antipsychotic medicines.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparin (a medicine for thinning the blood)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water tablets (diuretics).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laxatives.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Penicillin (an antibiotic).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amphotericin (for the treatment of fungal infections).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (a medicine for mental health problems).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steroids such as prednisolone.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pituitary hormone (ACTH).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat cancer.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amantadine (for the treatment of Parkinson&rsquo;s disease or for serious infections caused by viruses).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Barbiturates (a type of sedative also used to treat epilepsy).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbenoxolone (for treatment of oesophageal disease, or oral ulcers).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticholinergic agents such as atropine and biperiden.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine, a medicine used for organ transplant to avoid organ rejection.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines that may lead to enhancement of the antihypertensive effect such as baclofen (a medicine for relief of spasticity), amifostin (used in cancer treatment) and some antipsychotic medicines.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking an ACE‑inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Atacand Plus&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Taking Atacand Plus with food and drink (in particular alcohol)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Atacand Plus with or without food.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you are prescribed Atacand Plus, discuss with your doctor before drinking alcohol. Alcohol may make you feel faint or dizzy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">You must not take Atacand Plus if you are pregnant, might be pregnant, or are considering becoming pregnant. You must tell your doctor if you think you are (or might become) pregnant. Your doctor will ask you to stop taking Atacand Plus before you become pregnant or as soon as you know you are pregnant and may recommend another medicine instead of Atacand Plus. Atacand Plus may cause serious harm or even death to your baby if used during pregnancy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Tell your doctor if you are breast‑feeding or about to start breast‑feeding. Atacand Plus must not be used by mothers who are breast‑feeding.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">Some people may feel tired or dizzy when taking Atacand Plus. If this happens to you, do not drive or use any tools or machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Important information about some of the ingredients of Atacand Plus</strong></p><p dir="ltr">Atacand Plus contains lactose which is a type of sugar. If you have been told by doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take Atacand Plus exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. It is important to keep taking Atacand Plus every day.</p><p dir="ltr">The usual dose of Atacand Plus is one tablet once a day</p><p dir="ltr">Swallow the tablet with a drink of water.</p><p dir="ltr">Try to take the tablet at the same time each day. This will help you to remember to take it.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Atacand Plus than you should</strong></p><p dir="ltr">If you take more Atacand Plus than prescribed by your doctor, contact a doctor or pharmacist immediately for advice.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to take use Atacand Plus</strong></p><p dir="ltr">Do not take a double dose to make up for a forgotten tablet. Just take the next dose as normal.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop taking Atacand Plus</strong></p><p dir="ltr">If you stop taking Atacand Plus, your blood pressure may increase again. Therefore do not stop taking Atacand Plus without first talking to your doctor.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Atacand Plus can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be. Some of the side effects of Atacand Plus are caused by candesartan cilexetil and some are caused by hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Stop taking Atacand Plus and seek medical help immediately if you have any of the following allergic reactions:</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulties in breathing, with or without swelling of the face, lips, tongue and/or throat.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue and/or throat, which may cause difficulties in swallowing.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching of the skin (with raised lumps).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Atacand Plus may cause a reduction in number of white blood cells. Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. If this happens contact your doctor. Your doctor may occasionally do blood tests to check whether Atacand Plus has had any effect on your blood (agranulocytosis).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other possible side effects include:</p><p dir="ltr"><strong>Common (affects 1 to 10&nbsp;users in 100)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood test results<strong>:</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduced amount of sodium in your blood. If this is severe then you may notice weakness, lack of energy, or muscle cramps.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased or reduced amount of potassium in your blood, especially if you already have kidney problems or heart failure. If this is severe, you may notice tiredness, weakness, irregular heartbear or pins and needles.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased amount of cholesterol, sugar or uric acid in your blood.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sugar in your urine.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy/spinning sensation<strong> </strong>or weak.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory infection.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Uncommon (affects less than 1&nbsp;user in 100)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure. This may make you feel faint or dizzy.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, diarrhoea, constipation, stomach irritation.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, lumpy rash (hives), rash caused by sensitivity to sunlight.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Rare (affects less than 1&nbsp;user in 1,000)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of the skin or the whites of your eyes). If this happens to you, contact your doctor immediately.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on how your kidneys work, especially if you have kidney problems or heart failure.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in sleeping, depression, being restless.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or prickling in your arms or legs.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision for a short time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal heart beat.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulties (including lung inflammation and fluid in the lungs).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High temperature (fever).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas. This causes moderate to severe pain in the</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to blood vessels causing red or purple dots in the skin.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduction in your red or white blood cells or platelets. You may notice tiredness, an infection, fever or easy bruising.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe rash, that develops quickly, with blistering or peeling of the skin and possibly blistering in the mouth.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Very rare (affects less than 1&nbsp;user in 10,000)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain, pain in joints and muscles.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in how your liver is working, including inflammation of the liver (hepatitis).You may notice tiredness, yellowing of your skin and the whites of your eyes and flu like symptoms.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Acute respiratory distress (signs include severe shortness of breath, fever, weakness and confusion)</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye [choroidal effusion] or acute angle-closure glaucoma</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic and cutaneous lupus erythematosus (allergic condition which causes fever, joint pain, skin rashes which may include redness, blistering, peeling and lumps)</p><p dir="ltr">&nbsp;</p><p dir="ltr">If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the drug under 30&ordm;C.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Atacand Plus after the expiry date which is stated on the carton, blister pack or bottle. The expiry date refers to the last day of that month.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Atacand Plus contains</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">The active ingredients in Atacand Plus are candesartan cilexetil and hydrochlorothiazide. The tablets contain 16&nbsp;mg of candesartan cilexetil and 12.5&nbsp;mg of hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The other ingredients are carmellose calcium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, maize starch and macrogol. Atacand Plus 16 mg/12.5 mg contains iron oxide red (E172). Atacand Plus 16 mg/12.5 contains iron oxide yellow (E172).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>What Atacand Plus looks like and contents of the pack</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Atacand Plus 16/12.5&nbsp;mg tablets are peach, oval tablets with a score line on both sides and marked <!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:21pt;
 height:31pt' o:ole="">
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.wmz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="41" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Equation.3" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1742031000">
 </o:OLEObject>
</xml><![endif]-->&nbsp;.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Atacand Plus 16/12.5&nbsp;mg tablets are available in boxes with 28 tablets, conditioned in blister packs with 14 units.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Atacand Plus 16/12.5 mg tablets are peach, oval tablets with a score line on both sides and marked   .

Atacand Plus 16/12.5 mg tablets are available in boxes with 28 tablets, conditioned in blister packs with 14 units.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder</strong></p><p dir="ltr">Atacand Plus is manufactured in Sweden under the licence of:</p><p dir="ltr">AstraZeneca AG</p><p dir="ltr">Neuhofstrasse 34</p><p dir="ltr">6340 Baar</p><p dir="ltr">Switzerland</p><p dir="ltr">Candesartan cilexetil is manufactured under the licence of:</p><p dir="ltr">Takeda Pharmaceutical Company Limited, Japan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:35.5pt;height:12pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.wmz"
  o:title=""/>
</v:shape><![endif]--><img width="47" height="16" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p dir="ltr"><strong>Packed by:</strong></p><p dir="ltr">Tabuk pharmaceutical manufacturing company Tabuk, Saudi Arabia</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">For any information about this medicinal product, please contact the local representative</p><p dir="ltr">of the Marketing Authorisation Holder.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2023 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو عقار أتاكاند بلس وما هي دواعي استعماله</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">اسم الدواء هو أتاكاند بلس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وينتمي كانديسارتان سيليكسيتيل إلى مجموعة الأدوية التي يطلق عليها مضادات مستقبلات أنجيوتنسين II. وهو يؤدي إلى إرخاء وتوسعة الأوعية الدموية لديك. مما يساعد على انخفاض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي هيدروكلوروثيازيد إلى مجموعة من الأدوية تسمى الأدوية المدرة للبول (أقراص الماء). حيث تُساعد الجسم على التخلص من المياه والأملاح الزائدة مثل الصوديوم في البول. مما يساعد على انخفاض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وبالتالي يُستخدم لعلاج ارتفاع ضغط الدم (فرط ضغط الدم) لدى المرضى البالغين. ويحتوي الدواء على مكونين نشطين هما: كانديسارتان سيليكسيتيل وهيدروكلوروثيازيد. وهما يعملان معًا على خفض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد يصف طبيبك عقار أتاكاند بلس إذا لم يتحكم كانديسارتان سيليكسيتيل أو هيدروكلوروثيازيد وحده في ضغط الدم لديك على نحو مناسب.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناولي عقار أتاكاند بلس إذا كنتِ حاملاً أو تعتقدين باحتمالية الحمل أو تنوين أن تكوني حاملاً. ويجب أن تخبري طبيبك إذا كنت تعتقدين أنك حامل (أو قد تصبحين حاملاً). قد يسبب أتاكاند بلس ضررًا كبيرًا أو قد يتسبب في وفاة طفلك عند استخدامه أثناء الحمل (انظري قسم الحمل).</p><p dir="RTL"><strong>لا تتناول أتاكاند بلس في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية (فرط الحساسية) تجاه كانديسارتان سيليكسيتيل أو هيدروكلوروثيازيد أو أي من المكونات الأخرى لدواء أتاكاند بلس (انظر القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه مشتقات من فئة الأدوية المضادة للسكري. وإذا لم تكن متأكدًا من أن هذا ينطبق عليك، فيُرجى استشارة طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات حادة في الكُلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مرض كبدي حاد أو انسداد في الحويصلة الصفراوية (وهي مشكلة في تصريف إفرازات الصفراء من المرارة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستوى البوتاسيوم في الدم بشكل مستمر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع مستوى الكالسيوم في الدم بشكل مستمر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق أن تعرضت للنقرس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كان لديك مرض السكري أو اختلال وظائف الكلى ويتم معالجتك بأدوية خفض ضغط الدم المحتوية على اليسكيرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت غير متأكد من انطباق أي من هذه الحالات، فتحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار أتاكاند بلس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخّ الحرص عند تناول أتاكاند بلس</strong></p><p dir="RTL">قبل أو أثناء تناول أتاكاند بلس، اخبر طبيبك في حال:</p><p dir="RTL">- كنت مصابًا بمرض السكري.</p><p dir="RTL">- كانت لديك مشكلات في القلب أو الكبد أو الكُلى.</p><p dir="RTL">- خضعت مؤخرًا لعملية زراعة كلى.</p><p dir="RTL">- كنت تتقيأ، وعانيت مؤخرًا من القيء الحاد أو الإسهال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - كنت تعاني من مرض الغدة الكظرية المعروف بمتلازمة كون (يعرف أيضًا بفرط الألدوستيرونية الأولي).</p><p dir="RTL">- عانيت مسبقًا من المرض المُسمى الذئبة الحمامية (SLE)&rlm;&lrm;</p><p dir="RTL">- كنت تعاني من انخفاض ضغط الدم</p><p dir="RTL">- عانيت يومًا من سكتة دماغية.</p><p dir="RTL">- كنت مصابًا بالحساسية أو الربو.</p><p dir="RTL">- كنت تتناول أي من الأدوية التالية المستخدمة لعلاج ارتفاع ضغط الدم:</p><ul><li dir="RTL">مثبطات الإنزيم المُحَوِّل للأنجيوتنسين<strong> </strong>(ACE)<strong> </strong>(على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل، إلخ)، وخصوصاً إذا كانت لديك مشاكل في الكلى المتعلقة بمرض السكري.</li><li dir="RTL">اليسكيرين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بسرطان الجلد أو إذا تطورت لديك آفة جلدية مشبوهة أثناء</p><p dir="RTL">العلاج بهيدروكلوروثيازيد ، وخاصة الاستخدام طويل الأمد مع ارتفاع</p><p dir="RTL">الجرعات ، قد تزيد من خطر الإصابة ببعض أنواع سرطان الجلد والشفة (الجلد غير الميلانيني</p><p dir="RTL">سرطان). الحد من التعرض لأشعة الشمس وحماية بشرتك عند التعرض لأشعة الشمس أثناء</p><p dir="RTL">أخذ أتاكاند بلس.</p><p dir="RTL">- إذا كنت تعاني من انخفاض في الرؤية أو ألم في العين. قد تكون هذه أعراض تراكم السوائل في الطبقة الوعائية للعين (choroidal effusion) أو زيادة الضغط في عينك ويمكن أن تحدث في غضون ساعات إلى أسابيع من تناول اتاكاند بلس. هذا يمكن أن يؤدي إلى فقدان دائم للبصر ، إذا لم يتم علاجه. إذا كنت قد عانيت في وقت سابق من حساسية من البنسلين أو السلفوناميد ، فقد تكون أكثر عرضة للإصابة بهذا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في التنفس أو الرئة (بما في ذلك الالتهاب أو تراكم السوائل في الرئتين) بعد تناول هيدروكلوروثيازيد. إذا كنت تعاني من ضيق شديد في التنفس أو صعوبة في التنفس بعد تناول هذا الدواء ، فاستشر الطبيب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- قد يرغب طبيبك إلى فحص وظائف الكلى الخاصة بك، وضغط الدم، وكمية من المواد المنحلة بالكهرباء (مثل البوتاسيوم) في الدم على فترات منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أيضاً انظر إلى المعلومات تحت عنوان &quot; لا تتناول أتاكاند بلس &quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرغب طبيبك في رؤيتك عدة مرات وإجراء عدة اختبارات إذا تعرضت للحالات التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة خضوعك لعملية، فأخبر الطبيب أو طبيب الأسنان أنك تتناول عقار أتاكاند بلس. ويرجع ذلك إلى أن أتاكاند بلس عند إضافته إلى بعض أنواع عقارات التخدير، قد يسبب انخفاض في ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد يتسبب أتاكاند بلس في زيادة حساسية الجلد من التعرض للشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاستخدام لدى الأطفال</p><p dir="RTL">لم يتم إجراء أية تجارب على استخدام أتاكاند بلس مع الأطفال (أقل من 18 عامًا). ومن ثم يجب الامتناع عن إعطاء عقار أتاكاند بلس للأطفال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى</strong></p><p dir="RTL">يرجى أن تخبر طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أي أدوية أخرى بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية. قد يؤثر أتاكاند بلس على طريقة عمل بعض الأدوية الأخرى كما أن بعض الأدوية يمكنها أن تؤثر على أتاكاند بلس. إذا كنت تستخدم أنواعًا محددة من الأدوية، فقد يكون الطبيب في حاجة إلى إجراء بعض اختبارات الدم من وقت لآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم أي من الأدوية التالية بشكل محدد فقد يرغب طبيبك لتغيير الجرعة و / أو اتخاذ الاحتياطات الأخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تساعد على خفض ضغط الدم بما في ذلك حاصرات البيتا، اليسكيرين التي تحتوي على أدوية، وديازوكسيد، ومثبطات الإنزيم المُحَوِّل للأنجيوتنسين<strong> </strong>(ACE)<strong> </strong><strong>&rlm;</strong>مثل إنالابريل أو كابتوبريل أو ليزينوبريل أو راميبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للالتهاب غير الستيرويديّة (NSAIDs) مثل إيبوبروفين أو نابروكسين أو ديكلوفيناك أو سيليكوكسيب أو إيتوريكوكسيب (أدوية تؤخذ لتخفيف الألم والالتهاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليساليك (إذا كنت تتناول أكثر من 3 جم يوميًا) (دواء يؤخذ لتخفيف الألم والالتهاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم (أدوية تزيد من كمية البوتاسيوم في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات الكالسيوم أو فيتامين (د).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الخافضة للكوليسترول، مثل كوليستيبول أو كوليسترامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مرض السكري (أقراص أو حقن إنسولين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التحكم في ضربات القلب (المواد المضادة لاضطراب النّظم) مثل ديجوكسين وحاصرات بيتا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يؤثر عليها مستويات البوتاسيوم في الدم مثل بعض الأدوية المضادة للذُهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبارين (أدوية سيولة الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص المياه (مدرة للبول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المليّنات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنسلين (مضاد حيوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتيريسين (لعلاج العدوى الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يعالج مشاكل الصحة العقلية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات مثل البريدنيزولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرمون النخامي (ACTH).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعالجة للسرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين (لعلاج مرض باركنسون أو العدوى الخطيرة الناجمة عن الفيروسات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباربيتورات (نوع من المهدئات المستخدم أيضًا لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كربينوكسولون (لعلاج الأمراض المريئية أو القرحات الفموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات المفعول الكوليني مثل أتروبين وبِيبيريدين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سايكلوسبورين، وهو دواء مستخدم لزراعة الأعضاء لتجنب رفض العضو المزروع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي قد تؤدي إلى تعزيز التأثير الخافض لضغط الدم مثل باكلوفين (دواء لتخفيف الشلل التشنجي) وأميفوستين (مستخدم في علاج السرطان) وبعض الأدوية المضادة للذُهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مثبطات الإنزيم المُحَوِّل للأنجيوتنسين (ACE) أو اليسكيرين (أيضاً انظر المعلومات تحت العناوين &quot; لا تتناول أتاكاند بلس &quot; و &quot; توخّ الحرص عند تناول أتاكاند بلس&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أتاكاند بلس مع الطعام والشراب (وبالتحديد الكحول)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول أتاكاند بلس مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند وصف أتاكاند بلس لك، ناقش الأمر مع الطبيب قبل احتساء الكحول. قد يؤدي احتساء الكحول إلى شعورك بالضعف أو الدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تجنب تناول أتاكاند بلس إذا كنتِ حاملاً أو تعتقدين باحتمالية الحمل أو تنوين أن تكوني حاملاً. ويجب أن تخبري طبيبك إذا كنت تعتقدين أنك حامل (أو قد تصبحين حاملاً). سيطلب منك الطبيب التوقف عن تناول عقار أتاكاند بلس قبل الحمل أو بمجرد العلم بالحمل وقد يوصي ببعض الأدوية الأخرى بدلاً من أتاكاند. قد يسبب أتاكاند بلس ضررًا كبيرًا أو قد يتسبب في وفاة طفلك عند استخدامه أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة</u></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبري الطبيب إذا كنتِ تقومين بالرضاعة أو على وشك بدء الرضاعة. يجب تجنب استخدام أتاكاند بلس من جانب الأمهات اللاتي يرضعن طبيعيًا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يشعر بعض الأشخاص بالتعب أو الدوار عند تناول عقار أتاكاند بلس. إذا شعرت بذلك، فلا تقم بالقيادة أو تستخدم أية أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات أتاكاند بلس</strong></p><p dir="RTL">يحتوي أتاكاند بلس على اللاكتوز وهو أحد أنواع السكر. إذا أخبرك الطبيب أنّك لا تحتمل بعض أنواع السكر، فعليك الاتصال به قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عليك دومًا تناول أتاكاند بلس وفقًا لتوجيهات الطبيب تمامًا. يتعيّن عليك التحقق من طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكّدًا. من الهام الالتزام بتناول أتاكاند بلس يوميًا.</p><p dir="RTL">تعتبر الجرعة العادية من أتاكاند بلس هي قرص واحد يوميًا.</p><p dir="RTL">ابتلع القرص مع شربة ماء.</p><p dir="RTL">تناول القرص في الوقت نفسه يوميًا. سيساعدك ذلك على تذكر تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة من أتاكاند بلس أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت جرعة أتاكاند بلس أكثر من الموصوف بمعرفة الطبيب، فاتصل على الطبيب أو الصيدلي على الفور طلبًا للنصيحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول أتاكاند بلس</strong></p><p dir="RTL">لا تتناول جرعة مزدوجة لتعويض جرعة فائتة. فقط تناول الجرعة التالية كالمعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أتاكاند بلس</strong></p><p dir="RTL">إذا توقفت عن تناول أتاكاند بلس، فقد يزيد ضغط الدم مرة أخرى. ومن ثم لا تتوقف عن تناول أتاكاند بلس من دون إخبار الطبيب أولاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كانت لديك أسئلة أخرى حول استخدام هذا المنتج، فتحدث إلى طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في جميع الأدوية ، يمكن أن يتسبّب أتاكاند بلس في حدوث آثار جانبية على الرغم من أنها لا تصيب جميع المستخدمين. من الهام معرفة طبيعة تلك الآثار الجانبية. تحدث بعض الآثار الجانبية لدواء أتاكاند بلس بسبب مادة كانديسارتان سيليكسيتيل ويحدث البعض الآخر بسبب هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول أتاكاند بلس واطلب المساعدة الطبية على الفور إذا لاحظت وجود أيّ من التفاعلات التحسسية التالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس سواء تورم الوجه و/أو الشفتان و/أو اللسان و/أو الحلق أم لا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه و/أو الشفتان و/أو اللسان و/أو الحلق الذي قد يسبب صعوبات في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة جلدية شديدة (مصحوبة ببثور مرتفعة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من انخفاض في الرؤية أو ألم في العين. قد تكون هذه أعراض لتراكم السوائل في الطبقة الوعائية للعين أو زيادة الضغط في عينك ويمكن أن تحدث في غضون ساعات إلى أسابيع من تناول أتاكاند بلس. هذا يمكن أن يؤدي إلى فقدان دائم للبصر ، إذا لم يتم علاجه. إذا كنت قد عانيت سابقًا من حساسية من البنسلين أو السلفوناميد ، فقد تكون أكثر عرضة للإصابة بهذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب أتاكاند بلس انخفاض عدد كريات الدم البيضاء. قد تقل مقاومة العدوى لديك وقد تشعر بتعب أو عدوى أو حمى. وإذا حدث ذلك فاتصل على الطبيب. قد يقوم الطبيب من حين لآخر بإجراء بعض اختبارات الدم للتحقق من آثار أتاكاند بلس على الدم (ندرة المحببات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية المحتملة الأخرى ما يلي:</p><p dir="RTL"><strong>شائعة (تؤثّر في عدد يتراوح بين مستخدم إلى عشرة مستخدمين من أصل ١٠٠)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبار الدم<strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض نسبة الصوديوم في الدم. إذا كان ذلك شديدًا، فقد تشعر بالتعب أو نقص الطاقة بشكل عام أو تشنجات عضلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;زيادة أو انخفاض نسبة البوتاسيوم في الدم، خصوصًا إذا كانت لديك بالفعل مشكلات في الكُلى أو فشل القلب. وإذا حدث هذا على نحو حاد، فقد تلاحظ حدوث تعب أو ضعف أو عدم انتظام ضربات القلب أو الشعور بوخزٍ مثل الدبابيس والإبر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الكولسترول أو السكر أو حمض اليوريك في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكر في البول.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الإحساس بالدوخة/الدوار<strong> </strong>أو الضعف.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الصداع.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عدوى الجهاز التنفسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (تصيب أقل من 1 بين كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم. قد يؤدي هذا إلى شعورك بالضعف أو الدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية والإسهال والإمساك وتهيجات المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي والطفح الجلدي الكُتلي (الشرى) والطفح الناتج عن الحساسية تجاه أشعة الشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (تصيب أقل من 1 بين كل 1,000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار الجلد أو الجزء الأبيض من العينين). فإذا حدث هذا لك، فاتصل بطبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات على طريقة عمل الكلى، على وجه الخصوص إذا كنت تعاني من مشكلات في الكُلى أو فشل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم والاكتئاب والشعور بالتململ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز أو النقر في الذراعين أو القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية لمدة قصيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب غير الطبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات التنفس (بما في ذلك التهابات الرئة وإفراز السوائل في الرئة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة (الحمى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس. ويسبب هذا ألمًا من متوسط إلى حاد في المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأوعية الدموية الذي يتسبب في حدوث نقاط حمراء أو أرجوانية على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء أو البيضاء أو في نسبة الصفيحات. وقد تُعاني من التعب أو العدوى أو الحمى أو سهولة رضوض الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الحاد، الذي ينمو بسرعة مع ظهور البثور أو تقشر الجلد ومن المحتمل ظهور البثور في الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًا (تصيب أقل من 1 بين كل 10,000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه و/أو الشفتان و/أو اللسان و/أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر وألم في المفاصل والعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير طريقة عمل الكبد، بما في ذلك التهابات الكبد (التهاب الكبد).قد تلاحظ أنك تعاني من التعب واصفرار الجلد والأجزاء البيضاء من العين والأعراض المشابهة للأنفلونزا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; الضائقة التنفسية الحادة (تشمل العلامات ضيق التنفس الشديد والحمى والضعف والارتباك)</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتوفرة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في الرؤية أو ألم في عينيك بسبب ارتفاع الضغط علامات محتملة لتراكم السوائل في الطبقة الوعائية من العين أو زرق انسداد الزاوية الحاد الألم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية الجهازية والجلدية (حالة الحساسية التي تسبب الحمّى، وآلام المفاصل، وطفح جلدي قد يتضمن احمرار، بثور، تقشّر وكتل)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ازدادت خطورة أي من الآثار الجانبية، أو لاحظت ظهور أي آثار جانبية غير مذكورة في هذه النشرة ، فيرجى إعلام طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li><p dir="RTL"><strong>ما الذي يحتويه أتاكاند بلس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تعد المكونات الفعّالة في أتاكاند بلس هي كانديسارتان سيليكسيتيل وهيدروكلوروثيازيد. تحتوي الأقراص على 16 ملجم من كانديسارتان سيليكسيتيل و 12.5 ملجم من هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي كالسيوم كارميلوز وهيدروكسي بروبيل سليلوز ومونوهيدرات اللاكتوز وستيارات الماغنسيوم ونشا الذرة وماكروجول. يحتوي أتاكاند بلس 16 ملجم/12.5 ملجم على أكسيد الحديد الأحمر (E172). ويحتوي أتاكاند بلس 16 ملجم/12.5 ملجم على أكسيد الحديد الأصفر (E172).</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل أتاكاند بلس ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي أقراص أتاكاند بلس 16/12.5 ملجم على أقراص خوخية اللون وبيضاوية الشكل وبها خط محفور على كلا الجانبين ومميزة بالعلامة <!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:21pt;
 height:30.5pt' o:ole="">
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.wmz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="41" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Equation.3" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1742031236">
 </o:OLEObject>
</xml><![endif]-->&nbsp;.&rlm;</p><p dir="RTL">يمكن تقسيم القرص إلى نصفين متساويين بكسره على امتداد الخط المحفور على جانبيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر أقراص أتاكاند بلس 16/12.5 ملجم في علب تحتوي على 28 قرص، معدة في عبوات أشرطة تحتوي كل منها على 14 وحدة (قرص).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحتوي أقراص أتاكاند بلس 16/12.5 ملجم على أقراص خوخية اللون وبيضاوية الشكل وبها خط محفور على كلا الجانبين ومميزة بالعلامة A/CS .&rlm;</p><p dir="RTL">يمكن تقسيم القرص إلى نصفين متساويين بكسره على امتداد الخط المحفور على جانبيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر أقراص أتاكاند بلس 16/12.5 ملجم في علب تحتوي على 28 قرص، معدة في عبوات أشرطة تحتوي كل منها على 14 وحدة (قرص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حقوق التسويق</strong></p><p dir="RTL">أتاكاند بلس مصنوع في السويد بترخيص: أسترازينيكا أيه جي، نيوهوفستراسي 34، 6340 بار، سويسرا</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تصنيع كانديسارتان سيليكسيتيل بموجب ترخيص من:</p><p dir="RTL">شركة Takeda Pharmaceutical المحدودة، اليابان.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:35pt;height:12pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.wmz"
  o:title=""/>
</v:shape><![endif]--><img width="47" height="16" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p dir="RTL"><strong>تم تعبئته بواسطة :</strong></p><p dir="RTL">شركة تبوك للصناعات الدوائية المحدودة.</p><p dir="RTL">تبوك - المملكة العربية السعودية.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atacand Plus 16 mg/12.5 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One Atacand Plus 16 mg/12.5 mg tablet contains 16 mg candesartan cilexetil and 12.5 mg hydrochlorothiazide. Each tablet contains 68 mg lactose monohydrate.

For a full list of excipients, see section 6.1


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

Atacand Plus 16 mg/12.5 mg tablets are peach, oval, biconvex tablets with a score on both sides and

engraved A/CS .

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Atacand Plus is indicated for the:</p><p dir="ltr">Treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with candesartan cilexetil or hydrochlorothiazide monotherapy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Posology for hypertension</u></p><p dir="ltr">The recommended dose of Atacand Plus is one tablet once daily.</p><p dir="ltr">Dose titration with the individual components (candesartan cilexetil and hydrochlorothiazide) is recommended. When clinically appropriate, a direct change from monotherapy to Atacand Plus may be considered. Dose titration of candesartan cilexetil is recommended when switching from hydrochlorothiazide monotherapy. Atacand Plus may be administered in patients whose blood pressure is not optimally controlled with candesartan cilexetil or hydrochlorothiazide monotherapy or Atacand Plus at lower doses.</p><p dir="ltr">Most of the antihypertensive effect is usually attained within 4 weeks of initiation of treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><em>Elderly population</em></p><p dir="ltr">No dose adjustment is necessary in elderly patients.</p><p dir="ltr"><em>Patients with reduced blood volume</em></p><p dir="ltr">Dose titration of candesartan cilexetil is recommended in patients at risk for hypotension, such as patients with possible volume depletion (an initial dose of candesartan cilexetil of 4 mg may be considered in these patients).</p><p dir="ltr"><em>Patients with renal impairment</em></p><p dir="ltr">Dose titration is recommended in patients with mild to moderate renal impairment (creatinine clearance 30-80 ml/min/1.73 m<sup>2</sup> Body Surface Area (BSA)).</p><p dir="ltr">Atacand Plus is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min/1.73 m<sup>2</sup> BSA) (see section 4.3).</p><p dir="ltr"><em>Patients with hepatic impairment</em></p><p dir="ltr">Dose titration of candesartan cilexetil is recommended in patients with mild to moderate hepatic impairment.</p><p dir="ltr">Atacand Plus is contraindicated in patients with severe hepatic impairment and/or cholestasis (see section 4.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">The safety and efficacy of Atacand Plus in children from birth to adolescents under the age of 18 years have not been established. No data are available.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">Oral use.</p><p dir="ltr">Atacand Plus can be taken with or without food.</p><p dir="ltr">The bioavailability of candesartan is not affected by food.</p><p dir="ltr">There is no clinically significant interaction between hydrochlorothiazide and food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or to other sulfonamides. Hydrochlorothiazide is a sulfonamide.
-  Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
-  Severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2 BSA).
-  Severe hepatic impairment and/or cholestasis.
-  Refractory hypokalaemia and hypercalcaemia.
-  Gout.
-  The concomitant use of Atacand Plus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR< 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p dir="ltr">There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and the patient should be subject to regular close monitoring of renal function, electrolytes and blood pressure. ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal impairment</u></em></p><p dir="ltr">As with other agents inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible patients treated with Atacand Plus (see section 4.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Kidney transplantation</u></em></p><p dir="ltr">There is limited clinical evidence regarding Atacand Plus use in patients who have undergone renal transplantation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal artery stenosis</u></em></p><p dir="ltr">Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or renal artery stenosis in patients with a solitary kidney.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Intravascular volume depletion</u></em></p><p dir="ltr">In patients with intravascular volume and/or sodium depletion symptomatic hypotension may occur, as described for other agents acting on the renin-angiotensin-aldosterone system. Therefore, the use of Atacand Plus is not recommended until this condition has been corrected.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Anaesthesia and surgery</u></em></p><p dir="ltr">Hypotension may occur during anaesthesia and surgery in patients treated with AIIRAs due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Non-melanoma skin cancer</p><p dir="ltr">&nbsp;</p><p dir="ltr">A potential association of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been reported in two epidemiological case control studies based on Danish National cancer registry. Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC although a causal relationship has not been established.</p><p dir="ltr">Patients taking HCTZ should be informed of the association of NMSC with HCTZ use and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and adequate protection, when exposed to sunlight should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since even minor alterations of fluid and electrolyte balance may precipitate hepatic coma. There is no clinical experience with Atacand Plus in patients with hepatic impairment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Aortic and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)</u></em></p><p dir="ltr">As with other vasodilators, special caution is indicated in the treatment of patients suffering from haemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Primary hyperaldosteronism</u></em></p><p dir="ltr">Patients with primary hyperaldosteronism generally will not respond to antihypertensive agents acting through inhibition of the renin-angiotensin-aldosterone system. Therefore the use of Atacand Plus is not recommended in this population.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Electrolyte imbalance</u></em></p><p dir="ltr">Periodic determination of serum electrolytes should be performed at appropriate intervals. Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypercalcaemia, hypokalaemia, hyponatraemia, hypomagnesaemia and hypochloraemic alkalosis).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thiazide diuretics may decrease the urinary calcium excretion and may cause recurrent and slightly increased serum calcium concentrations. Marked hypercalcaemia may be a sign of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hydrochlorothiazide dose-dependently increases urinary potassium excretion which may result in hypokalaemia. This effect of hydrochlorothiazide seems to be less evident when combined with candesartan cilexetil. The risk for hypokalaemia may be increased in patients with cirrhosis of the</p><p dir="ltr">&nbsp;</p><p dir="ltr">liver, in patients experiencing brisk diuresis, in patients with an inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or adrenocorticotropic hormone (ACTH).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with candesartan cilexetil may cause hyperkalaemia, especially in the presence of heart failure and/or renal impairment. Concomitant use of Atacand Plus and ACE inhibitors, aliskiren, potassium-sparing diuretics, potassium supplements, salt substitutes or other medicinal products that increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Monitoring of potassium should be undertaken as appropriate.</p><p dir="ltr">Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Metabolic and endocrine effects</u></em></p><p dir="ltr">Treatment with a thiazide diuretic may impair glucose tolerance. Dose adjustment of antidiabetic medicinal products, including insulin, may be required. Latent diabetes mellitus may become manifest during thiazide therapy. Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy. At the doses contained in Atacand Plus, only minimal effects were observed. Thiazide diuretics increase serum uric acid concentration and may precipitate gout in susceptible patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Photosensitivity</u></em></p><p dir="ltr">Cases of photosensitivity reactions have been reported during use of thiazide diuretics (see section 4.8). If a photosensitivity reaction occurs, it is recommended to stop treatment. If re-administration of treatment is essential, it is recommended to protect areas exposed to the sun or to artificial UVA radiation.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Choroidal effusion, Acute Myopia and Angle-Closure Glaucoma</p><p dir="ltr">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Acute respiratory toxicity</p><p dir="ltr">Very rare severe cases of acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary oedema typically develops within minutes to hours after taking hydrochlorothiazide. At the onset, symptoms include dyspnoea, fever, worsening lung function and hypotension. If ARDS is suspected, Pemzek plus should be discontinued and appropriate treatment instituted. Hydrochlorothiazide must not be used in patients who have previously experienced ARDS after taking hydrochlorothiazide.</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>General</u></em></p><p dir="ltr">In patients whose vascular tone and renal function depend predominantly on the activity of the renin- angiotensin-aldosterone system (e.g. patients with severe heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system including AIIRAs, has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or atherosclerotic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p dir="ltr">Exacerbation or activation of systemic lupus erythaematosus has been reported with the use of thiazide diuretics.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The antihypertensive effect of Atacand Plus may be enhanced by other antihypertensives.</p><p dir="ltr">&nbsp;</p><p dir="ltr">This medicinal product contains lactose, as an excipient, and patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Pregnancy</u></em></p><p dir="ltr">Treatment with AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have a well-documented safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Substances which have been investigated in clinical pharmacokinetic studies include warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide and nifedipine. No pharmacokinetic interactions of clinical significance were identified in these studies.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The potassium depleting effect of hydrochlorothiazide could be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid derivates, steroids, ACTH).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant use of Atacand Plus and potassium-sparing diuretics, potassium supplements or salt substitutes or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Monitoring of potassium levels should be undertaken as appropriate (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Diuretic-induced hypokalaemia and hypomagnesaemia predisposes to the potential cardiotoxic effects of digitalis glycosides and antiarrhythmics. Periodic monitoring of serum potassium is recommended when Atacand Plus is administered with such medicinal products, and with the following medicinal products that could induce torsades de pointes:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class Ia antiarrhythmics (e.g. quinidine, hydroquinidine, disopyramide)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class III antiarrhythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperiodol)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Others (e.g. bepridil, cisapride, diphemanil, erythromycin iv, halofantrin, ketanserin, mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine iv)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with Angiotensin Converting Enzyme (ACE) inhibitors or hydrochlorothiazide. A similar effect has also been reported with AIIRAs. Use of candesartan and hydrochlorothiazide with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p dir="ltr">&nbsp;</p><p dir="ltr">As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p dir="ltr">The diuretic, natriuretic and antihypertensive effect of hydrochlorothiazide is blunted by NSAIDs. The absorption of hydrochlorothiazide is reduced by colestipol or cholestyramine.</p><p dir="ltr">The effect of nondepolarising skeletal muscle relaxants (e.g. tubocurarine) may be potentiated by hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements or Vitamin D must be prescribed, serum calcium levels should be monitored and the dose adjusted accordingly.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thiazide may increase the risk of adverse effects caused by amantadine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Postural hypotension may become aggravated by simultaneous intake of alcohol, barbiturates or anaesthetics.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with a thiazide diuretic may impair glucose tolerance. Dose adjustment of antidiabetic medicinal products, including insulin, may be required. Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hydrochlorothiazide may cause the arterial response to pressor amines (e.g. adrenaline) to decrease but not enough to exclude a pressor effect.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hydrochlorothiazide may increase the risk of acute renal insufficiency especially with high doses of iodinated contrast media.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant treatment with baclofen, amifostin, tricyclic antidepressants or neuroleptics may lead to enhancement of the antihypertensive effect and may induce hypotension.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Clinical trial data have shown that the incidence of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) is higher with dual blockade of the</p><p dir="ltr">renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em><u>Pregnancy</u></em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Angiotensin II Receptor Antagonists (AIIRAs):</em></p><p dir="ltr">&nbsp;</p><table cellpadding="0" cellspacing="0" dir="ltr" style="width:100%"><tbody><tr><td><p>Angiotensin II receptor antagonists should not be used during the first trimester of pregnancy (see section 4.4 Special warnings and precautions for use). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 Contraindications and 4.4 Special warnings and precautions for use).</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Epidemiological data regarding the risk of foetal harm following the use of ACE inhibitors during the first trimester of pregnancy have not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data for AIIRAs, similar risks may exist for this class of drugs.</p><p dir="ltr">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should receive alternative treatments which have a well-documented safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p dir="ltr">AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3 Preclinical safety data).</p><p dir="ltr">Should exposure to AIIRAs have occurred during the second trimester of pregnancy, an ultrasound check of renal function and skull is recommended.</p><p dir="ltr">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 Contraindications and 4.4 Special warnings and precautions for use).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hydrochlorothiazide:</em></p><p dir="ltr">There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p dir="ltr">Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimesters may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p dir="ltr">Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease. Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Lactation</u></em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Angiotensin II Receptor Antagonists (AIIRAs):</em></p><p dir="ltr">Because no information is available regarding the use of Atacand Plus during breastfeeding, Atacand Plus is not recommended and alternative treatments with better documented safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hydrochlorothiazide:</em></p><p dir="ltr">Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Atacand Plus during breast-feeding is not recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or tiredness may occur during treatment with Atacand Plus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In controlled clinical studies with candesartan cilexetil/hydrochlorothiazide, adverse reactions were mild and transient. Withdrawals from treatment due to adverse events were similar with candesartan cilexetil/hydrochlorothiazide (2.3-3.3%) and placebo (2.7-4.3%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical trials with candesartan cilexetil/hydrochlorothiazide, adverse reactions were limited to those that were reported previously with candesartan cilexetil and/or hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The table below presents adverse reactions with candesartan cilexetil from clinical trials and post marketing experience. In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The frequencies used in the tables throughout section 4.8 are: very common (&ge; 1/10), common</p><p dir="ltr">(&ge; 1/100, &lt; 1/10), uncommon (&ge; 1/1,000, &lt; 1/100), rare (&ge; 1/10,000, &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Respiratory infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p><p>disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and</p><p>agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition</p><p>disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperkalaemia, hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness/vertigo, headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Increased liver enzymes, abnormal</p><p>hepatic function or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue</p><p>disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure in susceptible patients (see</p><p>section 4.4)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">The table below presents adverse reactions with hydrochlorothiazide monotherapy usually with doses of 25 mg or higher.</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anaemia, bone marrow depression, haemolytic</p><p>anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperglycaemia, hyperuricaemia, electrolyte imbalance (including</p><p>hyponatraemia and hypokalaemia)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Sleep disturbances, depression,</p><p>restlessness</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Light-headedness, vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Transient blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Choroidal effusion, Acute myopia, acute angle-closure</p><p>glaucoma</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Postural hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Necrotising angiitis (vasculitis,</p><p>cutaneous vasculitis)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Respiratory complaints (including</p><p>pneumonitis and pulmonary oedema)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome (ARDS)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, loss of appetite, gastric</p><p>irritation, diarrhoea, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestatic</p><p>jaundice)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash, urticaria, photosensitivity</p><p>reactions</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Systemic lupus erythematosus,</p><p>cutaneous lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Muscle spasm</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Glycosuria</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Renal dysfunction and interstitial</p><p>nephritis</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weakness</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Investigations</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Fever</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Increases in cholesterol and triglycerides</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em>Symptoms</em></p><p dir="ltr">With regard to the pharmacological properties, overdose of candesartan cilexetil is likely to mainly cause symptomatic hypotension and dizziness. In individual case reports of overdose (of up to 672 mg candesartan cilexetil) patient recovery was uneventful.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The main effect of an overdose of hydrochlorothiazide is acute loss of fluid and electrolytes. Symptoms such as dizziness, hypotension, thirst, tachycardia, ventricular arrhythmias, sedation/impairment of consciousness and muscle cramps can also occur.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Management</em></p><p dir="ltr">No specific information is available on the treatment of overdose with Atacand Plus. The following measures are, however, suggested in case of overdose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When indicated, induction of vomiting or gastric lavage should be considered. If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of isotonic saline solution. Serum electrolytes and acid-base balance should be checked and corrected, if needed. Sympathomimetic medicinal products may be administered if the above-mentioned measures are not sufficient.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan can not be removed by haemodialysis. It is not known to what extent hydrochlorothiazide is removed by haemodialysis.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmaco-therapeutic group: Angiotensin II antagonists + diuretics, ATC code<strong>: </strong>C09DA06</p><p dir="ltr">&nbsp;</p><p dir="ltr">Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension and other cardiovascular disorders. It also has a role in the pathogenesis of organ hypertrophy and end organ damage. The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT1) receptor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan cilexetil is a prodrug which is rapidly converted to the active drug, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an AIIRA and binds selectively to AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan does not influence ACE or other enzyme systems usually associated with the use of ACE inhibitors. Since there is no effect on the degradation of quinines, or on the metabolism of other substances, such as substance P, AIIRAs are unlikely to be associated with cough. In controlled clinical trials comparing candesartan cilexetil with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. The antagonism of the AT1 receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg) once daily on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years, 21% aged 80 or above) with mild to moderate hypertension followed for a mean of</p><p dir="ltr">3.7 years (Study on COgnition and Prognosis in the Elderly). Patients received candesartan or placebo with other antihypertensive treatment added as needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction). There were</p><p dir="ltr">26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk 0.89, 95% CI 0.75 to 1.06, p=0.19).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hydrochlorothiazide inhibits the active reabsorption of sodium, mainly in the distal kidney tubules, and promotes the excretion of sodium, chloride and water. The renal excretion of potassium and magnesium increases dose-dependently, while calcium is reabsorbed to a greater extent. Hydrochlorothiazide decreases plasma volume and extracellular fluid and reduces cardiac output and blood pressure. During long-term therapy, reduced peripheral resistance contributes to the blood pressure reduction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Large clinical studies have shown that long-term treatment with hydrochlorothiazide reduces the risk for cardiovascular morbidity and mortality.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan and hydrochlorothiazide have additive antihypertensive effects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In hypertensive patients, Atacand Plus results in a dose-dependent and long-lasting reduction in arterial blood pressure without reflex increase in heart rate. There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment. After administration of a single dose of candesartan cilexetil, onset of the antihypertensive effect generally occurs within</p><p dir="ltr">2&nbsp; hours. With continuous treatment, most of the reduction in blood pressure is attained within four weeks and is sustained during long-term treatment. Atacand Plus once daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between peak and trough effects during the dosing interval. In a double-blind randomised study, Atacand Plus 16 mg/12.5 mg once daily reduced blood pressure significantly more, and controlled the blood pressure of significantly more patients, than the losartan/hydrochlorothiazide combination 50 mg/12.5 mg once daily.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In double-blind, randomised studies, the incidence of adverse events, especially cough, was lower during treatment with Atacand Plus than during treatment with combinations of ACE inhibitors and hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In two clinical studies (randomised, double-blind, placebo controlled, parallel group) including 275 and 1524 randomised patients<strong>, </strong>respectively, the candesartan cilexetil/hydrochlorothiazide combinations 32 mg/12.5 mg and 32 mg/25 mg resulted in blood pressure reductions of 22/15 mmHg and 21/14 mmHg, respectively, and were significantly more effective than the respective monocomponents.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a randomised, double-blind, parallel group clinical study including 1975 randomised patients not optimally controlled on 32 mg candesartan cilexetil once daily, the addition of 12.5 mg or 25 mg hydrochlorothiazide resulted in additional blood pressure reductions. The candesartan cilexetil/hydrochlorothiazide combination 32 mg/25 mg was significantly more effective than the 32 mg/12.5 mg combination, and the overall mean blood pressure reductions were 16/10 mmHg and 13/9 mmHg, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan cilexetil/hydrochlorothiazide is similarly effective in patients irrespective of age and gender.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Currently there are no data on the use of candesartan cilexetil/hydrochlorothiazide in patients with renal disease/nephropathy, reduced left ventricular function/heart failure and post myocardial infarction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)) and VA NEPHRON-D (The Veterans Affairs Nephrology in Diabetes) have examined the combined use of an ACE inhibitor and an angiotensin II receptor blocker.</p><p dir="ltr">&nbsp;</p><p dir="ltr">ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension was observed to monotherapy. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor blockers. ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both<sup>1</sup>. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Concomitant administration of candesartan cilexetil and hydrochlorothiazide has no clinically significant effect on the pharmacokinetics of either substance.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><sup>1</sup> Translator&rsquo;s note: there is a stray &lsquo;och&rsquo;, meaning &lsquo;and&rsquo; in the Swedish source text.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Absorption and distribution</u></em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Candesartan cilexetil</em></p><p dir="ltr">Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The relative bioavailability of a tablet formulation of candesartan cilexetil compared with the same oral solution is approximately 34% with very little variability. The mean peak serum concentration (C<strong>max</strong>) is reached 3-4 hours following tablet intake. The candesartan serum concentrations increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration versus time curve (AUC) of candesartan is not significantly affected by food.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of candesartan is 0.1 l/kg.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hydrochlorothiazide</em></p><p dir="ltr">Hydrochlorothiazide is rapidly absorbed from the gastrointestinal tract with an absolute bioavailability of approximately 70%. Concomitant intake of food increases the absorption by approximately 15%. The bioavailability may decrease in patients with cardiac failure and pronounced oedema.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The plasma protein binding of hydrochlorothiazide is approximately 60%. The apparent volume of distribution is approximately 0.8 l/kg.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Biotransformation and elimination</u></em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Candesartan cilexetil</em></p><p dir="ltr">Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4. Based on <em>in vitro </em>data, no interaction would be expected to occur <em>in vivo </em>with medicinal products whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life (t&frac12;) of candesartan is approximately 9 hours. There is no accumulation following multiple doses. The half-life of candesartan remains unchanged (approximately 9 h) after administration of candesartan cilexetil in combination with hydrochlorothiazide. No additional accumulation of candesartan occurs after repeated doses of the combination compared to monotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about</p><p dir="ltr">0.19 ml/min/kg. The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of <sup>14</sup>C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hydrochlorothiazide</em></p><p dir="ltr">Hydrochlorothiazide is not metabolised and is excreted almost entirely as unchanged drug by glomerular filtration and active tubular secretion. The terminal half-life of hydrochlorothiazide is approximately 8 hours. Approximately 70% of an oral dose is eliminated in the urine within 48 hours. The half-life of hydrochlorothiazide remains unchanged (approximately 8 h) after administration of hydrochlorothiazide in combination with candesartan cilexetil. No additional accumulation of hydrochlorothiazide occurs after repeated doses of the combination compared to monotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Pharmacokinetics in special populations</u></em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Candesartan cilexetil</em></p><p dir="ltr">In elderly subjects (over 65 years), Cmax and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects. However, the blood pressure response and the incidence of adverse events are similar after a given dose of Atacand Plus in young and elderly patients (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients with mild to moderate renal impairment, Cmax and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but the terminal half-life was not altered, compared to patients with normal renal function. The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. The terminal half-life of candesartan was approximately doubled in patients with severe renal impairment. The pharmacokinetics in patients undergoing haemodialysis were similar to those in patients with severe renal impairment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2). There is no experience in patients with severe hepatic impairment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hydrochlorothiazide</em></p><p dir="ltr">The terminal half-life of hydrochlorothiazide is prolonged in patients with renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There were no qualitative new toxic findings with the combination compared to that observed for each component. In preclinical safety studies candesartan itself had effects on the kidneys and on red cell parameters at high doses in mice, rats, dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). Effects on the kidneys (such as regeneration, dilatation and basophilia in tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion. Addition of hydrochlorothiazide potentiates the nephrotoxicity of candesartan. Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells. These changes were considered to be caused by the pharmacological properties of candesartan and to be of little clinical relevance.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Foetotoxicity has been observed in late pregnancy with candesartan. The addition of hydrochlorothiazide did not significantly affect the outcome of foetal development studies in rats, mice or rabbits (see section 4.6).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Candesartan and hydrochlorothiazide both show genotoxic activity at very high concentrations/doses. Data from <em>in vitro </em>and <em>in vivo </em>genotoxicity testing indicate that candesartan and hydrochlorothiazide are unlikely to exert any mutagenic or clastogenic activity under conditions of clinical use.</p><p dir="ltr">&nbsp;</p><p dir="ltr">There was no evidence that either substance is carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carmellose calcium Hydroxypropylcellulose</p><p>Iron oxide red, (E172) (only 16 mg/12.5 mg and 32 mg/25 mg)</p><p>Iron oxide yellow, (E172) (only 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg)</p><p>Lactose monohydrate</p><p>Magnesium stearate</p><p>Maize starch</p><p>Macrogol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special temperature storage conditions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>16 mg/12.5 mg tablets: PVC-PVDC/Al blister packs of 28 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AG
Neuhofstrasse 34
6340 Baar
Switzerland


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>